EMAGLIFLOZIN M12.5/850

EMAGLIFLOZIN M 12.5/850 Tablet is a combination of Empagliflozin (12.5 mg) and Metformin (850 mg), specially formulated for the management of Type 2 Diabetes Mellitus. This dual therapy helps in controlling blood sugar levels, improving insulin sensitivity, and reducing glucose reabsorption by the kidneys.

By combining the benefits of SGLT2 inhibition (Empagliflozin) with metabolic control (Metformin), it provides effective long-term glycemic control and helps lower the risk of diabetes-related complications such as heart disease, kidney damage, and neuropathy.

✅ Key Benefits:

• Improves blood sugar control in Type 2 Diabetes

• Reduces glucose reabsorption and increases urinary glucose excretion

• Enhances insulin sensitivity and reduces liver glucose production

• Supports weight management and may lower risk of cardiovascular issues